리포좀 제제 의약품 개발 동향

• 영문명: Recent Advances in Liposomal Drug Product Development
• 발행기관: 대한약학회
• 저자명: 김재천(Jae Cheon Kim) 나동희(Dong Hee Na)
• 간행물 정보: 『약학회지』제65권 제4호(2021년), 246~257쪽, 전체 12쪽
• 주제분류: 의약학 > 기타의약학
• 파일형태: PDF
• 발행일자: 2021.08.31

영문 초록

Liposomes are spherical vesicles composed of a bilayer (uni-lamellar) and/or a concentric series of multiple bilayer (multi-lamellar) separated by aqueous compartments formed by amphipathic molecules, such as phospholipids. Liposomes deliver drugs via encapsulation in inner aqueous or lipid compartments and have advantages such as control of drug release and distribution, alleviation of toxicity, and drug targeting. Since the launch of the first liposomal drug Doxil？？, a variety of products using a liposomal drug delivery system have been developed and commercialized. Recently, several drug candidates developed with sophisticated and diverse technologies have been undergoing clinical trials. In this review, the pharmaceutical characteristics of approved liposomal drugs are overviewed, and the recent advances in liposome technology through candidates in clinical trials are highlighted.

목차

서 론(Introduction)

리포좀 제제 의약품 현황(Liposomal Drug Products)

리포좀 제제 의약품 개발 동향(Liposomal Drugs under Clinical Development)

고 찰(Discussion)

결 론(Conclusion)

감사의 말씀(Acknowledgment)

Conflict of Interest

References

키워드

Liposome Doxil Liposomal drug products Drug delivery system Nanomedicine